Ignite Creation Date:
2025-12-25 @ 4:15 AM
Ignite Modification Date:
2026-03-04 @ 1:38 PM
Study NCT ID:
NCT01646320
Status:
COMPLETED
Last Update Posted:
2016-06-22
First Post:
2012-07-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
Sponsor:
AstraZeneca
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
MB102-129
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None